Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Targeting Heat Shock Protein 90 (Hsp90) is a validated strategy in cancer treatment.
• Previous research identified pyrazole derivatives as Hsp90 inhibitors disrupting the Hsp90-Cdc37 interaction.
• TAS-116, an Hsp90 inhibitor, is approved for gastrointestinal stromal tumors.

Purpose of the Study:

• To optimize pyrazole derivatives into potent covalent Hsp90 inhibitors.
• To develop novel compounds with improved Absorption, Distribution, Metabolism, and Excretion (ADME) properties.
• To evaluate the antitumor efficacy of optimized compounds, specifically compound 39 (DDO-6691).

Main Methods:

• Systematic structure-activity relationship (SAR) optimization of pyrazole derivatives.
• Development of a new covalent warhead for enhanced Hsp90 inhibition.
• In vitro assessment of compound 39 sensitivity in HCT-116 cells versus Cdc37-knockout cells.
• In vivo evaluation of compound 39 in HCT-116 xenograft mouse models.

Main Results:

• Compound 39 (DDO-6691) was developed with improved ADME properties and enhanced antitumor activity.
• HCT-116 cells showed significantly greater sensitivity to compound 39 compared to Cdc37-knockout cells.
• Compound 39 demonstrated potent inhibition of tumor growth in HCT-116 xenograft mouse models.

Conclusions:

• Covalent Hsp90 inhibition targeting the Hsp90-Cdc37 complex is a promising therapeutic strategy.
• Compound 39 (DDO-6691) represents a novel mechanistic approach for cancer treatment.
• Further development of covalent Hsp90 inhibitors warrants investigation for clinical application.